challenging compared to traditional pharmaceuticals because these therapies often involve living cells or genetic materials susceptible to contamination. Sterility assurance strategies must therefore be robust, comprehensive, and tailored to the product and process complexities.

Closed systems are manufacturing set-ups where the product is not exposed to the external environment during processing, storage, or transfer. Conversely, open systems are those where product contact interfaces with ambient conditions, raising contamination risks.

Pharma microbiology in ATMP manufacturing focuses on the control of viable and non-viable contaminants that can compromise product quality or patient safety. This scope includes:

• Microbial bioburden – naturally occurring microorganisms on raw materials or introduced during processing.
• Environmental monitoring – surveillance of cleanrooms and utilities such as water systems and clean steam systems.
• Endotoxin control – especially critical for cell therapies where pyrogenic substances can cause serious patient reactions.

Key to sterility assurance is the validation and strict control of GMP utilities such as Purified Water (PW) and Water for Injection (WFI), which are widely used for cleaning, formulation, and steam generation. The choice of system configuration (closed or open) directly influences the required level of control over these utilities and the associated microbiological risks.

Regulatory frameworks such as FDA 21 CFR Parts 210 and 211, EU GMP Annex 1, and PIC/S guidance offer clear stipulations on environmental and aseptic processing controls that relate directly to system design decisions in ATMP manufacturing.

Step 2: Evaluating Closed Systems: Microbiology and Utility Considerations

Closed systems offer intrinsic advantages for microbiological control. By minimizing product exposure to the environment, the risk of contamination from personnel, air, surfaces, and equipment is significantly reduced. This step reviews the elements central to maintaining sterility in a closed ATMP processing environment.

2.1 Designing for Closed Processing

Operationally, closed systems use aseptic connectors, tubing assemblies, and controlled environments such as isolators or restricted-access barrier systems (RABS). This physical separation enables stricter environmental classifications, often allowing ISO 5 classification at the critical processing zones even within an ISO 7 background.

Material transfers, sampling, and manipulation all occur without direct contact or exposure, substantially reducing bioburden introduction. However, these systems demand rigorous validation of components, connections, and closure integrity because breaches can be difficult to detect and remediate.

2.2 GMP Utilities in Closed Systems

• Water Systems (PW & WFI): Purified Water and Water for Injection are cornerstones in ATMP workflows for cleaning, formulation, and other critical steps. In closed systems, continuous monitoring of microbial counts and endotoxin levels is essential to prevent contamination propagation. Automated retrievable samples and validated sterile sampling ports minimize exposure during monitoring.
• Clean Steam: Utilized for sterilization, clean steam must be free from endotoxins and viable microorganisms. In closed systems, validation of steam generator design and steam line integrity ensures consistent sterilization without microbial ingress.

2.3 Microbiological Monitoring and Control

Environmental monitoring in closed systems focuses on verifying that no microbial contamination percolates into the critical zones through penetrations or materials. Particulate and microbial counts should consistently meet rigorous limits, typically following guidance in EU GMP Annex 1. Routine surface sampling, air monitoring, and personnel monitoring (in non-critical zones) are requisite.

Bioburden assessments on product contact surfaces, incoming supplies, and containers are equally crucial. The use of closed single-use systems can markedly reduce the risk of biofilm formation in water systems, thus lowering an overall bioburden burden.

2.4 Endotoxin Control

Endotoxin testing and control are imperative in ensuring patient safety, as pyrogenic substances can trigger adverse inflammatory reactions. Filtration integrity testing combined with endotoxin monitoring of utilities (especially PW and WFI lines) forms a critical part of the closed system’s microbiological oversight.

Regular sterilization cycles using validated clean steam ensure that condensate and sterile filter integrity are maintained, reducing endotoxin carryover. Automated monitoring instruments support real-time analytics and early detection of endotoxin excursions.

Step 3: Examining Open Systems: Challenges and Mitigation Strategies in ATMP Manufacturing

Open systems, where product exposure to the external environment is unavoidable, inherently carry increased microbiological risk. This step outlines the microbiology, GMP utilities considerations, and control strategies for open system operation.

3.1 Characteristics of Open Systems

ATMP processes involving open manipulations—such as manual dosing, filling, or sampling in laminar airflow workbenches or cleanrooms—require stringent environmental controls and procedural discipline. The product-exposed environment must maintain extremely low levels of airborne and surface contamination, necessitating ISO 5 or better conditions at the point of exposure and ISO 7 or better background environments.

3.2 Microbiological Risks in Open Processing

Because the product is exposed to ambient air, personnel, and surfaces, there is an increased risk of microbial bioburden introduction. The inability to maintain a sealed environment means contamination control depends heavily on operational controls and environmental monitoring to detect and mitigate breaches promptly.

Personnel gowning, aseptic technique training, and controlled airflows are essential elements to reduce contamination risk. Environmental monitoring programs in open systems typically include:

• Frequent viable air sampling using active samplers or settle plates.
• Surface contact plates on critical surfaces and equipment.
• Personnel glove and gown fingertip sampling.

3.3 GMP Utility Requirements for Open Systems

Water systems supplying PW and WFI to open system processes must be carefully designed to manage microbiological risks. Open systems usually require:

• Validated sanitization cycles of water loops to avoid biofilm formation that can increase microbial load.
• Additional non-sterile filtration steps or UV sterilization of water points to reduce microbial ingress.
• Constant temperature control and flow velocity in water distribution to prevent stagnation.

Clean steam use in open environments entails challenges in avoiding microbial or endotoxin contamination during transfer and sterilization cycles. Thorough validation and routine testing of steam generators and distribution lines are mandatory to ensure microbial and endotoxin limits are consistently met.

3.4 Mitigating Microbiological Risks in Open Systems

Balancing the inherent exposure risks of open systems requires a multifaceted approach:

• Robust Environmental Monitoring: Higher frequency and locations of sampling in critical zones ensure timely detection of rising bioburden or endotoxin levels.
• Enhanced Cleaning and Disinfection Protocols: Rigorous cleaning with validated sporicidal agents and documented procedures are essential to reduce microbial loads on surfaces and equipment.
• Personnel Training and Hygiene: Structured programs focus on aseptic techniques and hygiene compliance to minimize contamination opportunities.
• Process Controls: Minimizing duration and extent of open exposure through process optimization reduces contamination risk.

Validation of aseptic processes, including media fills and contamination control strategies, must specifically address the open system challenges aligned with WHO GMP principles.

Step 4: Integrating Environmental Monitoring and Microbial Risk Management into ATMP GMP Utilities

Environmental monitoring and risk management form the backbone of microbiological control in both closed and open ATMP manufacturing systems. Their integration into GMP utilities enhances sterility assurance and product safety.

4.1 Designing an Effective Environmental Monitoring Program

An effective environmental monitoring (EM) program includes comprehensive sampling of air, surfaces, personnel, and utilities. Key features include:

• Sampling Locations: Critical processing zones, pass-through areas, gowning rooms, and clean utility systems like water loops and clean steam generators.
• Frequency: Determined by risk assessment and regulatory expectations. More frequent sampling is typical in highly controlled closed systems with critical operations.
• Methodology: Use of validated sampling devices such as active air samplers capable of microbial capture, contact plates on surfaces, and swab methods for irregular equipment parts.
• Data Trending: Longitudinal data analysis to detect trends, spikes, or shifts in bioburden or particulate counts facilitating proactive interventions.

4.2 Microbial Risk Assessment and Control

Risk identification and assessment process steps:

• Identify contamination sources related to product contact surfaces, personnel, materials, and GMP utilities.
• Analyze potential impacts on critical quality attributes such as sterility and endotoxin levels.
• Establish control strategies based on risk ranking, including enhanced cleaning, aseptic processing improvements, or utility system upgrades.
• Implement monitoring triggers and alert systems for immediate corrective actions upon excursion detection.

4.3 GMP Utility Qualification with Microbiology in Focus

Utility systems such as water and clean steam must be fully qualified under current GMP standards to ensure they consistently meet microbiological specifications:

• Design Qualification (DQ): Confirm utility design suits process needs, including closed or open system requirements.
• Installation Qualification (IQ): Document installation per design specifications with no compromises that could introduce microbiological risks.
• Operational Qualification (OQ): Verify utility control systems function correctly, including microbiological monitoring equipment.
• Performance Qualification (PQ): Demonstrate utility system can reliably produce water or steam within microbial and endotoxin specifications during routine operations.

This rigorous qualification underpins sterility assurance and regulatory compliance across global requirements.

Step 5: Final Considerations for Implementing Microbiology Controls in ATMP Manufacturing

Choosing between closed and open systems in ATMP manufacturing depends on multiple factors including product nature, batch sizes, and facility capabilities. However, from a microbiological standpoint, the preference for closed systems is supported by the inherent reduction in contamination risk and improved sterility assurance.

Nevertheless, open systems continue to play a role where process constraints or product characteristics necessitate them, demanding comprehensive microbiological control programs and robust GMP utilities management.

Final best practices for microbiological controls in ATMP manufacturing include:

• Align system design with regulatory expectations for sterility and contamination control based on guidance such as EU GMP Annex 1 and FDA aseptic processing guidance.
• Implement continuous environmental monitoring programs employing validated and sensitive methods to detect low microbial loads promptly.
• Maintain stringent qualification and routine monitoring of GMP utilities including PW, WFI, and clean steam to prevent contamination sources.
• Design aseptic processes and utilities with closed system technologies where feasible, with thorough validation and integrity testing for components and connectors.
• Engage cross-functional teams including QA, QC, clinical operations, and regulatory affairs to continuously evaluate and improve microbiological risk management and sterility assurance.

By adopting a structured, scientifically rigorous, and regulatory-aligned approach to microbiology considerations in ATMP manufacturing, pharmaceutical manufacturers in the US, UK, and EU can ensure compliant, safe, and efficacious therapies that meet the highest standards of patient care.